Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 studyHervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology|December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialJeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Blood Advances|May 7, 2025
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated resultsMazyar Shadman, John M Burke, Jennifer Cultrera, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Cancer Medicine|May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study InvestigatorsTara Graff, Ian Flinn, Jeff P Sharman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|May 19, 2019
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 studyHervé Tilly, Franck Morschhauser, Nancy L Bartlett, et al.
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology|December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialJeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Blood Advances|May 7, 2025
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated resultsMazyar Shadman, John M Burke, Jennifer Cultrera, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Cancer Medicine|May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study InvestigatorsTara Graff, Ian Flinn, Jeff P Sharman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Pageof 8